Algert Global’s Heron Therapeutics HRTX Stock Holding History

Algert Global’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-12,899	Closed	-$239K	–	408
2019 Q3	$239K	Buy	+12,899	New	+$237K	0.09%	249

Other funds holding HRTX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Algert Global's HRTX Position: Q4 2019 in Review

Algert Global sold out of Heron Therapeutics (HRTX) in Q4 2019, closing a stake of 12,899 shares — an estimated $239K sold.

Algert Global first reported a position in HRTX in Q3 2019 and held it in 1 quarter. The position peaked at $239K in Q3 2019. 199 funds tracked by Wall St. Rank hold HRTX as of Q4 2019.

Algert Global reported no remaining Heron Therapeutics position as of Q4 2019 after selling out during the quarter.
Algert Global sold 12,899 Heron Therapeutics shares in Q4 2019, an estimated $239K.
Algert Global first reported a position in Heron Therapeutics in Q3 2019 and held it in 1 quarter.
Algert Global's Heron Therapeutics position peaked at $239K in Q3 2019.
199 funds tracked by Wall St. Rank held Heron Therapeutics as of Q4 2019.

Based on Algert Global's 13F filing for Q4 2019, filed 18 Feb 2020.